Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513747 · ClinicalTrials.gov registry record · Phase 3
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT00513747 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 84 participants.
The verdict
NCT00513747, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fludarabine together with rituximab may kill more cancer cells. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving fludarabine together with rituximab early is more effective than giving fludarabine and rituximab after observation in treating chronic lymphocytic leukemia. PURPOSE: This randomized phase III trial is studying fludarabine and rituximab to compare how well they work when given early or after observation in treating patients with previously untreated chronic lymphocytic leukemia.
Interventions
- BIOLOGICAL rituximab
- DRUG fludarabine phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513747
The ClinicalTrials.gov registry entry for NCT00513747 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00513747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513747 about?
NCT00513747 is a clinical study titled "Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer ...
What is the current status of trial NCT00513747?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2008-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00513747?
The interventions under investigation include: rituximab (BIOLOGICAL), fludarabine phosphate (DRUG).
Who is sponsoring clinical trial NCT00513747?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.